Publications:

Short-Term Responders of Non-Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms.

Translational Oncology

Xu, Yanjun Y; Tong, Xiaoling X; Yan, Junrong J; Wu, Xue X; Shao, Yang W YW; Fan, Yun Y

Publication Date: 2018-12

Variant appearance in text: ARID1A: L2281F

PubMed Link: 30196239

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page